Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ipratropium bromide monohydrate (Ipratropium bromide hydrate) 是一种毒蕈碱拮抗剂,结构上与阿托品相关,但它通常被认为对吸入使用更安全、更有效。它用于各种支气管疾病、鼻炎和抗心律失常。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 100 | 现货 | ||
25 mg | ¥ 143 | 现货 | ||
50 mg | ¥ 197 | 现货 | ||
100 mg | ¥ 297 | 现货 | ||
200 mg | ¥ 397 | 现货 | ||
500 mg | ¥ 597 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 150 | 现货 |
产品描述 | Ipratropium bromide monohydrate (Ipratropium bromide hydrate) is a muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. |
激酶实验 | VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated compound in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs[1]. |
别名 | Ipratropium bromide hydrate, 溴化异丙托品单水合物 |
分子量 | 430.38 |
分子式 | C20H32BrNO4 |
CAS No. | 66985-17-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 200 mM
DMSO: 200 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.3235 mL | 11.6176 mL | 23.2353 mL | 58.0882 mL |
5 mM | 0.4647 mL | 2.3235 mL | 4.6471 mL | 11.6176 mL | |
10 mM | 0.2324 mL | 1.1618 mL | 2.3235 mL | 5.8088 mL | |
20 mM | 0.1162 mL | 0.5809 mL | 1.1618 mL | 2.9044 mL | |
50 mM | 0.0465 mL | 0.2324 mL | 0.4647 mL | 1.1618 mL | |
100 mM | 0.0232 mL | 0.1162 mL | 0.2324 mL | 0.5809 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ipratropium bromide monohydrate 66985-17-9 Neuroscience AChR Ipratropium bromide hydrate ischaemia/reperfusion Ipratropium bromide Hydrate Ipratropium bromide Monohydrate Ipratropium bromide asthma Sch 1000 bromide Ipratropium Bromide I/R chronic obstructive pulmonary disease 溴化异丙托品单水合物 mAChR Muscarinic acetylcholine receptor inhibit Inhibitor inhibitor